IPO Update: Schrodinger Readies $150 Million IPO
Schrodinger has filed proposed terms for its U.S. IPO. The company sells drug discovery software and develops drug candidates in-house. SDGR has a bifurcated business model, is producing increasing operating losses, and the IPO isn’t cheap, so I’ll watch it from the sidelines. Schrodinger (SDGR) has filed to raise $150 million from the sale of …
News story posted on 2020-01-30T01:39:00.0000000Z
